Faron Reports 20% Disease Control Rate in Final MATINS Melanoma Study Data

• Faron Pharmaceuticals will present final MATINS melanoma results at ESMO 2026 in Madrid, October 23-27.
• Bexmarilimab alone achieved disease control in some patients whose metastatic melanoma resisted prior immunotherapy; survival differences were not statistically significant.
• Exploratory findings suggested immune activation during treatment, supporting the rationale for combining bexmarilimab with a checkpoint inhibitor.
• The ongoing BLAZE trial tests bexmarilimab with nivolumab in immunotherapy-resistant melanoma and lung cancer; its first patient was dosed October 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.